Fibrosis

Fibrosis is commonly described as arising as a consequence of inflammation or other injury. In the supplied grounding, chronic inflammation and wound-healing responses are repeatedly associated with fibrotic change. The grounding also links fibrosis to autoimmune and vasculopathic disease in systemic sclerosis, but does not support broader causal claims beyond that context.

The grounding supports a mechanism in which injury- or inflammation-driven signaling promotes abnormal wound healing, cell proliferation and differentiation, and deposition of extracellular matrix and fibrous connective tissue. Transforming growth factor beta is highlighted as a key mediator, with overexpression associated with epithelial-mesenchymal transition and fibrotic tissue remodeling. Oxidative stress, innate immunity, and cytokine signaling are also co-studied as part of the biological network underlying fibrosis.

Chronic inflammation and prior tissue injury are supported risk factors in the supplied material. In systemic sclerosis, autoimmunity and vasculopathy precede fibrosis and are therefore associated with fibrotic disease development. The grounding does not support additional general risk factors.

The supplied grounding supports management at the modality level rather than specific regimens. Diagnostic imaging and surgery are listed as covered aspects, and immunomodulatory drugs are noted in systemic sclerosis, although no therapy is described as reversing or slowing fibrosis in that disease. The literature also points to targeting TGF-beta signaling as a therapeutic strategy under investigation.